Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
1
13%
Ph phase_3
5
63%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 35 (62.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

A Study of KHK4827 in Patients With Systemic Sclerosis

NCT04368403
completedphase_3

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

NCT03957681
completedphase_3

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

NCT02982005
completedphase_3

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

NCT04061252
completedphase_3

A Phase 3 Clinical Study of KHK4827

NCT01782924
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04368403Phase 1

A Study of KHK4827 in Patients With Systemic Sclerosis

Completed
NCT03957681Phase 3

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Completed
NCT02982005Phase 3

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Completed
NCT04061252Phase 3

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Completed
NCT01782924Phase 3

A Phase 3 Clinical Study of KHK4827

Completed
NCT01782937Phase 3

An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

Completed
NCT01748539Phase 2

A Phase 2 Clinical Study of KHK4827

Completed
NCT01488201Phase 1

A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8